PMID: 2859987
If preferred our Healthcare practitioners are available if you wish to talk to them on 02 8212 4404
An exception is glicentin and its cleavage product oxyntomodulin, the concentrations of which need to be combined to match the amount of secreted GLP-1 [41,53]
Follow-up may depend on diabetes status, kidney disease, other medications, baseline abnormalities, dose changes, symptoms, and rate of weight loss
This creates a murky scenario: Questionable efficacy: The exact potency and composition of these concoctions remain an enigma, raising doubts about their true effectiveness in triggering weight loss
Insulin replacement therapy regimens in T2DM In patients with T2D who fail to achieve glycemic targets despite optimization of basal insulin, structured intensification of therapy becomes necessary